NCT00369252View on ClinicalTrials.gov

Phase I Study of Nimotuzumab in Solid Tumours

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

June 30, 2005

Conditions

Advanced and/or Metastatic Solid Tumours

Interventions

DRUG

Nimotuzumab (TheraCIM h-R3)

Trial Locations (1)

Unknown

Princess Margaret Hospital, Toronto

Sponsors

Lead Sponsor

Collaborators (1)

CIMYM BioSciences

All Listed Sponsors

collaborator

CIMYM BioSciences

OTHER

lead

YM BioSciences

INDUSTRY

NCT00369252 - Phase I Study of Nimotuzumab in Solid Tumours | Biotech Hunter | Biotech Hunter